Patents Examined by Susan Ungar
  • Patent number: 7541437
    Abstract: The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: June 2, 2009
    Assignee: University of Maryland, Baltimore
    Inventors: Douglas D. Ross, L. Austin Doyle, Lynne V. Abruzzo
  • Patent number: 7449181
    Abstract: A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: November 11, 2008
    Assignee: Sumitomo Pharmaceuticals Company Limited
    Inventors: Toshihiro Noguchi, Akemi Baba, Mitsuharu Hanada
  • Patent number: 7429452
    Abstract: Polynucleotide and polypeptide UKW are specific for pancreatic tumors. Diagnosis of UKW is therefore valuable for diagnosis of pancreatic tumors. Antibodies against UKW are, besides their value in diagnosis, useful as therapeutic agents for the treatment of pancreatic tumors.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: September 30, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Malte Buchholz, Thomas Gress, Stephanie Loesch, Ulrich Weidle
  • Patent number: 7427399
    Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: September 23, 2008
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-chi Jia, Jean Gudas
  • Patent number: 7419807
    Abstract: A high molecular weight (“HMW”) protein of Chlamydia, the amino acid sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. Also disclosed are prophylactic and therapeutic compositions, comprising the HMW protein, a fragment thereof, or an antibody that specifically binds the HMW protein or a portion thereof, or the nucleotide sequence encoding the HMW protein or a fragment thereof, including vaccines.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: September 2, 2008
    Assignee: Emergent Product Development Gaithersburg Inc.
    Inventors: W. James Jackson, John L. Pace
  • Patent number: 7416862
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: August 26, 2008
    Assignee: Wyeth
    Inventors: Lynn A. Doucette-Stamm, David Bush
  • Patent number: 7407656
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: August 5, 2008
    Assignees: The Regents of the University of California, Agensys, Inc.
    Inventors: Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovits
  • Patent number: 7405077
    Abstract: The results herein identify Sp17 as a novel cancer-testis antigen in multiple myeloma. Sp17 recombinant protein was generated from E. coli. A CD8 predominant CTL line was generated that was able to lyse autologous targets in a Sp17-dependent HLA class I-restricted manner, using dendritic cells as the antigen-presenting cells and DOTAP to deliver the Sp17 protein to the dendritic cells. A combination of HLA-matched and mismatched antibody-enriched fresh myeloma tumor cells and myeloma cell lines were used as targets for the recombinant protein-propagated CTL. The findings of target cell lysis suggest that the Sp17 protein produced by Sp17+ tumor cells are processed and presented in vivo and that the CTL epitopes are presented in association with HLA class I molecules in a concentration and configuration recognized by recombinant protein-propagated CTL.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: July 29, 2008
    Assignee: Albany Medical College
    Inventors: Seah H. Lim, Maurizio Chiriva-Internati, Zhiqing Wang
  • Patent number: 7393531
    Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: July 1, 2008
    Assignee: Arius Research Inc.
    Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay, Alison L. Ferry
  • Patent number: 7388071
    Abstract: Telomerase peptides that bind MHC are disclosed. The instant application also discloses vaccines containing said peptides and methods of using said peptides to enhance a CTL response against mammalian cancer cells.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: June 17, 2008
    Assignee: The Regents of the University of California
    Inventor: Maurizio Zanetti
  • Patent number: 7381701
    Abstract: The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof, to treat cancer in mammals.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: June 3, 2008
    Assignee: The Borad of Trustees of the University of Illinois
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Anita Chaudhari, Arsenio Fialho, Yonghua Zhu
  • Patent number: 7381407
    Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM?) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM? allows the use of an immunoenzymatic assay for their detection.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: June 3, 2008
    Assignee: Medarex, Inc.
    Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William Thomas Tino
  • Patent number: 7375183
    Abstract: This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequences for mesothelin, recombinant cells expressing it, methods for targeting and/or inhibiting the growth of cells bearing mesothelin, methods for detecting the antigen and its expression level as an indication of the presence of tumor cells, and kits for such detection.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: May 20, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira Pastan, Kai Chang
  • Patent number: 7368261
    Abstract: To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are shared across the majority of Neisseria, particularly N. meningitidis and N. gonorrhoeae.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: May 6, 2008
    Assignee: Novartis Vaccines and Diagnostics SRL
    Inventor: Rino Rappuoli
  • Patent number: 7364743
    Abstract: A nucleotide sequence encoding a fusion protein of PTD and CEA. The nucleotide sequence includes a CEA-encoding nucleotide sequence into which a PTD-encoding nucleotide sequence is inserted.
    Type: Grant
    Filed: June 29, 2004
    Date of Patent: April 29, 2008
    Assignee: Catholic University Industry Academic Cooperation Foundation
    Inventors: Tai-gyu Kim, Hyun-il Cho, Chang-hyeok An, Won-kyung Kang, Seong-taek Oh
  • Patent number: 7361354
    Abstract: There is disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognizing at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: April 22, 2008
    Assignee: Viralytics Limited
    Inventor: Darren R. Shafren
  • Patent number: 7361342
    Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
    Type: Grant
    Filed: January 20, 2004
    Date of Patent: April 22, 2008
    Assignee: Arius Research Inc.
    Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
  • Patent number: 7358347
    Abstract: The invention relates to the discovery of a novel tumor suppressor gene which is associated with multiple endocrine neoplasia type 1. The gene has been designated MEN1 and the gene product is menin. The absence of this protein and associated mutations in the corresponding gene have been identified in individuals suffering from multiple endocrine neoplasia type 1. The identification of this marker for multiple endocrine neoplasia type 1 has diagnostic uses as well as for gene therapy.
    Type: Grant
    Filed: March 4, 1998
    Date of Patent: April 15, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Settara Chandrasekharappa, Siradanahalli Guru, Pachiappan Manickam, Francis S. Collins, Michael R. Emmert-Buck, Larisa V. Debelenko, Irina A. Lubensky, Lance A. Liotta, Sunita K. Agarwal, Allen M. Spiegel, A. Lee Burns, Stephen J. Marx, Zhengping Zhuang
  • Patent number: 7354583
    Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: April 8, 2008
    Assignee: Amgen, Inc.
    Inventors: Tsutomu Arakawa, Yoshiko Kita
  • Patent number: RE40811
    Abstract: The invention relates to in vivo peripheralization of CD34+ cells by administering anti-VLA-4 antibodies or anti-VCAM-1 antibodies.
    Type: Grant
    Filed: November 15, 1993
    Date of Patent: June 30, 2009
    Assignee: Board of Regents of the University of Washington
    Inventor: Thalia Papayannopoulou